medcelerator · clinician one-pager

Heart Pill for Obstructive HCM from About 66 Pounds

Camzyos (mavacamten) — oral treatment for symptomatic obstructive HCM from about 66 lb

FDA Approved · United States · October 17, 2026

Condition: Obstructive Hypertrophic Cardiomyopathy

Who this is for

This is for families living with symptomatic obstructive hypertrophic cardiomyopathy when the person weighs at least 30 kg (about 66 lb). It explains the US prescribing-information expansion that added eligible pediatric patients to Camzyos (mavacamten), the REMS and echo path, and what SCOUT-HCM showed on the outflow gradient. It is not approved under 30 kg, not a local-pharmacy fill, and not an approval outside the United States for this pediatric wording on sources checked here. Authorized is not funded.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

General resources for further research

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/camzyos-mavacamten-pediatric-ohcm